3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Lung Neoplasms
8
Neoplasm Metastasis
6
Breast Neoplasms
6
Thyroid Neoplasms
4
Prostatic Neoplasms
4
Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Urinary Bladder Neoplasms
2
Pleural Effusion
2
Ovarian Neoplasms
2
Kidney Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Medullary
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thyroid cancer, medullary
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Relapsed Pediatric Solid Tumor
1
Recurrence
1
Rectal Neoplasms
1
Precancerous Conditions
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Non-small Cell Lung Cancer Metastatic
1
Interventions
Gemcitabine
45
Cisplatin
34
Oxaliplatin
23
Capecitabine
17
Fluorouracil
13
Leucovorin
12
pembrolizumab
11
lenvatinib
11
durvalumab
10
S 1 (combination)
10
Irinotecan
10
Bevacizumab
9
apatinib
7
Nivolumab
7
tremelimumab
6
Trastuzumab
5
envafolimab
4
atezolizumab
4
Injections
4
Docetaxel
4
trametinib
3
titanium silicide
3
tislelizumab
3
irinotecan sucrosofate
3
camrelizumab
3
Radiotherapy
3
Drug Therapy
3
zanidatamab
2
toripalimab
2
surufatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Biliary Tract Neoplasms
×
vandetanib
×
Clear all
NCT00753675
2016-10-10
VANGOGH
Sanofi
Phase 2
Completed
174 enrolled
12 charts